Vertex Pharma enters Russell 1000 value, shares reflect mixed benchmark shift
29.06.2026 - 10:39:04 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 10:38.
Vertex Pharma (US92532F1003) sees its index footprint reshaped this week. The Nasdaq-listed biotech has been added to the Russell 1000 Value Index while being dropped from the Russell 1000 Growth benchmark, according to index provider data reported by MarketScreener.
What the Russell changes show
MarketScreener states that Vertex Pharmaceuticals Incorporated, which trades on Nasdaq under the ticker VRTX, has been included in the Russell 1000 Value Benchmark. In the same set of changes, the company was removed from the Russell 1000 Growth Benchmark, highlighting a shift in how the stock is classified across style indices.
The Russell 1000 Value and Russell 1000 Growth indices are widely followed by institutional investors managing large-cap U.S. equity portfolios. Both sit within the broader Russell 1000 family tracked by many index funds and ETFs, making Vertex Pharma's reclassification relevant for passive flows and benchmark-aware active managers.
How the shares trade on Nasdaq
Vertex Pharma shares trade on the NasdaqGS in the United States, with MarketScreener citing a last price of 491.34 US dollars in recent trading for Vertex Pharmaceuticals Incorporated. Zacks notes that the stock has recently closed at 444.41 dollars in a session where it gained around 2 percent, outpacing the S&P 500's 1.75 percent daily rise, underlining robust relative performance in large-cap biotech.
Vertex isn’t alone in the biotech space; peers like Amgen and Gilead Sciences also sit in major U.S. indices such as the S&P 500 and are held broadly in sector and style funds. Analyst-focused portals like Zacks continue to track Vertex Pharma's moves versus these peers and broad benchmarks.
More news and data on the Vertex Pharma shares
For a broader view of Vertex Pharma's price history, index membership and corporate disclosures, the topic hub and Investor Relations site offer detailed background.
The therapies behind the stock
Vertex Pharma's core business centers on treatments for cystic fibrosis, led by its flagship triple-combination therapy Trikafta (also marketed as Kaftrio in some regions), which targets the underlying cause of the disease by improving CFTR protein function. The company supplements this franchise with a pipeline in pain, gene-editing collaborations in sickle cell disease, and other serious conditions, aiming for durable cash flows from specialty medicines.
Where the Vertex shares trade today
The Vertex Pharma shares (US92532F1003) trade on NasdaqGS, with MarketScreener most recently quoting the stock at 491.34 US dollars as of 2026-06-26, 16:00 Eastern Time.
Key data on the Vertex Pharma shares
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- WKN: 882807
- Ticker: VRTX
- Trading venue: NasdaqGS
- Price (as of 2026-06-26, 16:00): 491.34 USD
- Market cap: about 126 billion USD (as of late June 2026, per Nasdaq and analyst estimates)
- Sector / industry: Health Care / Biotechnology
- Index membership: S&P 500, Nasdaq-100, Russell 1000 Value (recent addition), former member of Russell 1000 Growth
- Next earnings date: scheduled around early August 2026 per company guidance and consensus calendars, not yet officially fixed.
Disclaimer: This article provides factual information on Vertex Pharma and its shares and does not contain any investment advice, recommendation or solicitation to buy or sell securities.
